More on Arena Pharmaceuticals (ARNA): Q2 EPS comes up short but beats top line estimates. Total...

|About: Arena Pharmaceuticals, Inc. (ARNA)|By:, SA News Editor

More on Arena Pharmaceuticals (ARNA): Q2 EPS comes up short but beats top line estimates. Total revenue jumped over 500% Y/Y, however the increase was primarily the result of the $20M milestone payment earned under its marketing and supply agreement with Japanese drug maker Eisai. Bottom line results were hit by higher losses from the revaluation of derivative liabilities. Shares -3.6% AH.